CD4 and neoplasm: Further studies indicated that when used as a first-line therapy in combination with chemotherapy and ICIs for non-squamous NSCLC, NEO-PV-01 could induce CD4+ T cells with effector and cytotoxic features, highlighting its potential in reshaping the tumor immune microenvironment [75].